Follow the Pundits
Tag: hub-hedge
Citadel’s 2025 Scorecard: No Fireworks, Just Relentless Discipline
Citadel delivered another disciplined year in 2025 — not flashy, but formidable. Here’s what Ken Griffin’s fortress is really doing, and what it means for investors.
Revisiting The Case of CRISPR Therapeutics: Still Crisp, Still Risky, Still Dangerously Alluring
CRISPR Therapeutics (CRSP) has the first widely approved CRISPR-based therapy, huge insider buying near today’s price, and institutions (including ARK) deep in the name — while shorts pile on. Crisp setup, risky execution, dangerously alluring upside. 🧬🎯
Fundamental Research–Driven Fund Voss Capital Buys PAR Technology: Time to Shop?
PAR Technology is shifting from legacy hardware to a unified restaurant SaaS platform. After Voss Capital’s $7.1M buy, massive institutional ownership, and heavy short interest, the setup looks like an inflection-point story—high upside if execution clicks, sharp downside if it doesn’t.
Funds Still Love Meta Platforms — Should Retail Add on Dips?
Funds remain heavily invested in Meta Platforms as AI boosts ads and cash flow — but at today’s price, patience may still pay off.
John Rogers’ Ariel Investments Loves Madison Square Garden Entertainment: Should You?
MSGE owns some of the world’s most iconic entertainment venues. Demand is strong — but leverage and price argue for patience.
Nvidia Is a Top-Five Stock Held by Hedge Funds: Should You Buy — or Even Hold?
Nvidia is the crown jewel of AI and a top hedge-fund holding. The company is stellar — but is the stock still worth buying in 2026?
Hedge Funds Miller Value and Värde Partners Love Nabors Industries’ Cheap Shares, Deleveraging, and Saudi Aramco JV
Hedge funds are circling Nabors Industries — and not by accident. With aggressive deleveraging, a Saudi Aramco joint venture, and valuation metrics that still scream skepticism, NBR may be one of energy’s most misunderstood value plays.
Buffett Steps Down as CEO — Should You Step Away from Berkshire?
Buffett steps aside as CEO. The cash pile is massive. The machine still hums. Should long-term investors stay the course with Berkshire Hathaway?
Michael Burry Has 38% of His Portfolio in Lululemon: Time To Wear The Pants?
Michael Burry just made Lululemon a top portfolio holding. With valuation down, buybacks up, and shorts watching — is it time to wear the pants?
Insiders Are Buying Under Armour: Strong Suit or Skip the Knight-Mare?
Under Armour trades over 90% below its all-time high—but insiders are buying aggressively. Is this a rare turnaround opportunity or a classic value trap? Let’s break it down.